Ani Pharmaceuticals (ANIP) Net Income towards Common Stockholders (2011 - 2026)

Ani Pharmaceuticals (ANIP) has 16 years of Net Income towards Common Stockholders data on file, last reported at $29.5 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders rose 93.07% year-over-year to $29.5 million; the trailing twelve-month figure through Mar 2026 stood at $91.4 million (up 503.11% YoY), and the FY2025 full-year result was $77.2 million, up 483.08% from the prior year.
• Net Income towards Common Stockholders climbed to $29.5 million in Q1 2026, from $27.5 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $29.5 million in Q1 2026 to a low of -$24.6 million in Q3 2024.
• A 5-year average of $3.2 million and a median of $1.0 million in 2023 frame the typical range for Net Income towards Common Stockholders.
• Across the five-year window, Net Income towards Common Stockholders sank 25451.85% in 2022 and surged 1623.23% in 2024, its largest moves.
• Tracing ANIP's Net Income towards Common Stockholders over 5 years: stood at -$4.6 million in 2022, then surged by 116.11% to $749000.0 in 2023, then plunged by 1526.17% to -$10.7 million in 2024, then jumped by 357.35% to $27.5 million in 2025, then climbed by 7.28% to $29.5 million in 2026.
• Business Quant data shows ANIP's Net Income towards Common Stockholders at $29.5 million in Q1 2026, $27.5 million in Q4 2025, and $26.3 million in Q3 2025.